Neurizon Therapeutics Limited has released a press release.
Update on PharmAust Canine Cancer Trials
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Clinical Trials Update
- PharmAust receives $210k prepayment of forecast R&D rebate
- MPL tablets arrive in Melbourne for MND Clinical Trial
- PharmAust Expands Lymphoma Canine Trial to the USA
- PharmAust Receives $708k R&D Tax Incentive Refund
Later from Neurizon Therapeutics
- First Patient in US Canine Cancer Trials Begins Treatment
- First Patient Dosed in MND Phase 1/2 Trial
- DNDi contract extension for PharmAust subsidiary Epichem
- MND Trial Completes Enrolment of First Patient Cohort
- PharmAust Canine Trial Update
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics